Tisch Multiple Sclerosis Research Center Of New York Inc

Programs: The tisch ms research center's mission is to conduct medical research directed toward finding the cause and eventual cure for multiple sclerosis. In 2017, the tisch ms research center expanded its laboratory, building a state- of-the art cgmp (current good manufacturing practices) cell production facility, the regenerative medicine laboratory, to facilitate the fda-approved phase ii stem cell trial slated to begin in the fall of 2018. Other program accomplishments include the following: we have made advances in our biomarker research. In 2017 dr. Harris, senior research scientist, and dr. Sadiq, chief research scientist, published an invited review of the field of spinal fluid biomarkers in multiple sclerosis in the journal "degenerative neurological and neuromuscular disease". Additional advances were made in understanding mechanisms of disease progression. Dr. Sadiq in conjunction with dr. Liu, a former assistant research scientist at the center, published a study, describing blood brain barrier dysfunction in a mouse model of multiple sclerosis, in the journal "immunity, inflammation, and disease". Drs harris and sadiq also published a study describing the role of fetuin-a in modulating the innate immune response in multiple sclerosis in the journal "plos one".

as an academic facility, the tisch ms research center provides educational and training resources for ms researchers and medical professionals. Fellowships in ms research are offered to physicians and scientists interested in entering or expanding their work in this field. The center had three publications in 2017, a publication in the journal "degenerative neurological and neuromuscular disease", a publication in the journal "immunity, inflammation, and disease" and a publication in the journal